Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J. Straus DJ, et al. Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2. Lancet Haematol. 2021. PMID: 34048680 Clinical Trial.
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K; Polish Adult Leukemia Group. Wrzesień-Kuś A, et al. Eur J Haematol. 2003 Sep;71(3):155-62. doi: 10.1034/j.1600-0609.2003.00122.x. Eur J Haematol. 2003. PMID: 12930315 Clinical Trial.
Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma.
Centkowski P, Brydak L, Machała M, Kalinka-Warzocha E, Błasińska-Morawiec M, Federowicz I, Walewski J, Wegrzyn J, Wołowiec D, Lech-Marańda E, Sawczuk-Chabin J, Biliński P, Warzocha K; Polish Lymphoma Research Group. Centkowski P, et al. J Clin Immunol. 2007 May;27(3):339-46. doi: 10.1007/s10875-007-9073-3. Epub 2007 Mar 8. J Clin Immunol. 2007. PMID: 17345151
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
Kalinka-Warzocha E, Wajs J, Lech-Maranda E, Ceglarek B, Holowiecki J, Federowicz I, Walewski J, Czyz J, Robak T, Warzocha K; Polish Lymphoma Research Group. Kalinka-Warzocha E, et al. Cancer. 2008 Jul 15;113(2):367-75. doi: 10.1002/cncr.23558. Cancer. 2008. PMID: 18470902 Free article. Clinical Trial.
Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
Hus I, Jawniak D, Gorska-Kosicka M, Butrym A, Dzietczenia J, Wrobel T, Grzegorz M, Lech-Maranda E, Warzocha K, Waszczuk-Gajda A, Jedrzejczak WW, Krawczyk-Kulis M, Kyrcz-Krzemien S, Poplawska L, Walewski J, Dmoszynska A. Hus I, et al. Chemotherapy. 2013;59(4):280-9. doi: 10.1159/000357468. Epub 2014 Jan 21. Chemotherapy. 2013. PMID: 24457828
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B, Budziszewska BK, Rybka J, Gil L, Subocz E, Długosz-Danecka M, Zawirska D, Waszczuk-Gajda A, Iskierka-Jażdżewska E, Kopacz A, Szymczyk A, Czyż J, Lech-Marańda E, Warzocha K, Jamroziak K. Puła B, et al. Anticancer Res. 2018 May;38(5):3025-3030. doi: 10.21873/anticanres.12557. Anticancer Res. 2018. PMID: 29715135
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A. Straus DJ, et al. Blood. 2020 Mar 5;135(10):735-742. doi: 10.1182/blood.2019003127. Blood. 2020. PMID: 31945149 Free article. Clinical Trial.
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B, Iskierka-Jazdzewska E, Dlugosz-Danecka M, Szymczyk A, Hus M, Szeremet A, Drozd-Sokolowska J, Waszczuk-Gajda A, Zaucha JM, Holojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Osowiecki M, Knopinska-Posluszny W, Dudzinski M, Zawirska D, Subocz E, Halka J, Pluta A, Wichary R, Kumiega B, Budziszewska BK, Jurczak W, Lech-Maranda E, Giannopoulos K, Robak T, Jamroziak K. Pula B, et al. Anticancer Res. 2020 Jul;40(7):4059-4066. doi: 10.21873/anticanres.14403. Anticancer Res. 2020. PMID: 32620653
125 results